BioVersys Announces Publication of BV100 Phase 1 Clinical Data in Journal of Antimicrobial Agents and Chemotherapy

Core Insights - BioVersys AG announced the publication of Phase 1 clinical trial data for BV100, a novel antibacterial product targeting multi-drug resistant infections, in the Journal of Antimicrobial Agents and Chemotherapy [1][3]. Product Development - BV100 is an intravenous formulation of rifabutin designed to combat MDR hospital infections caused by Acinetobacter baumannii, including carbapenem-resistant strains [2][7]. - The Phase 1 trial demonstrated a dose-proportional pharmacokinetic profile, with BV100 being generally safe and well tolerated [3][8]. - A Phase 2 clinical trial for BV100 in Ventilator Associated Bacterial Pneumonia (VABP) patients showed a 50% relative reduction in all-cause mortality compared to best available therapy [3][4]. Clinical Trials - BV100 has advanced to a global registration Phase 3 clinical trial (RIV-TARGET) for patients with HABP/VABP suffering from CRAB infections, with the first patient expected to be dosed soon and results anticipated in H2 2027 [4][5]. - A global open-label Phase 2b clinical differentiation trial (RIV-CARE) will begin in H1 2026, comparing BV100 with best available therapy across multiple regions, with interim analysis expected by the end of 2026 [5][6]. Market Context - Acinetobacter baumannii is a significant global healthcare threat due to its high resistance rates, with BioVersys forecasting over one million annual carbapenem-resistant infections in hospitals worldwide, which carry mortality rates up to 50% [9][10]. - The company focuses on addressing the high unmet medical need for new treatments against life-threatening resistant bacterial infections, particularly in nosocomial settings [10].